SEATTLE GENETICS INC's ticker is SGENXXXX and the CUSIP is 812578102. A total of 297 filers reported holding SEATTLE GENETICS INC in Q2 2018. The put-call ratio across all filers is 1.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,073,000 | +11.3% | 9,300 | +10.2% | 0.33% | +8.5% |
| Q4 2019 | $964,000 | -2.7% | 8,436 | -27.3% | 0.30% | +3.4% |
| Q3 2019 | $991,000 | -74.5% | 11,605 | -79.3% | 0.30% | -66.5% |
| Q2 2019 | $3,882,000 | +40.8% | 56,092 | +48.9% | 0.88% | +43.0% |
| Q1 2019 | $2,758,000 | +20.7% | 37,659 | -6.6% | 0.62% | +11.4% |
| Q4 2018 | $2,285,000 | -20.4% | 40,334 | +8.3% | 0.55% | +3.6% |
| Q3 2018 | $2,872,000 | -9.8% | 37,240 | -22.4% | 0.53% | -13.3% |
| Q2 2018 | $3,185,000 | +23.9% | 47,974 | -2.3% | 0.62% | +28.9% |
| Q1 2018 | $2,570,000 | +4.9% | 49,099 | +7.2% | 0.48% | -5.9% |
| Q4 2017 | $2,449,000 | -18.6% | 45,784 | -17.2% | 0.51% | -39.4% |
| Q3 2017 | $3,010,000 | +48.1% | 55,319 | +40.8% | 0.84% | +39.4% |
| Q2 2017 | $2,033,000 | -13.2% | 39,295 | +5.5% | 0.60% | +2.7% |
| Q1 2017 | $2,341,000 | – | 37,246 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 50,060,240 | $5,775,950,000 | 35.57% |
| Lagoda Investment Management, L.P. | 72,969 | $8,419,000 | 9.97% |
| Avidity Partners Management LP | 580,000 | $66,920,000 | 9.25% |
| Arabesque Asset Management Ltd | 14,807 | $1,708,000 | 3.53% |
| Boxer Capital, LLC | 400,000 | $46,152,000 | 3.15% |
| Woodline Partners LP | 364,333 | $42,037,000 | 3.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,900 | $6,557,000 | 2.99% |
| SECTORAL ASSET MANAGEMENT INC | 107,000 | $12,346,000 | 2.37% |
| Capital International, Inc./CA/ | 1,197,659 | $138,186,000 | 2.33% |
| Bain Capital Public Equity Management II, LLC | 169,641 | $19,573,000 | 2.29% |